"Cardiac Rehabilitation in Patients With Hypertrophic Cardiomyopathy".

Sponsor
Institute of Cardiology, Warsaw, Poland (Other)
Overall Status
Unknown status
CT.gov ID
NCT03178357
Collaborator
(none)
60
1
2
40.7
1.5

Study Details

Study Description

Brief Summary

Hypertrophic cardiomyopathy (HCM) is the most common hereditary disease characterized by left ventricular hypertrophy and consequently left ventricular diastolic dysfunction. Its prevalence is estimated at around 0.2% in the general population. HCM is the most common cause of sudden cardiac death due to cardiovascular disease in young athletes, accounting for one third of deaths. HCM patients often have symptoms of heart failure. The ESC recommendations for heart failure (HF) from 2016 recommend exercise training regardless of ejection fraction to improve exercise capacity, quality of life, and reduction in hospitalizations due to HF. Meanwhile, for many years, HCM was equivalent to exercise training limitation. According to the 2014 ESC guidelines, it is recommended for patients with HCM to avoid sports practice. However the results of Edelmann et al. research, suggest that physical training leads to a significant clinical improvement in patients with diastolic dysfunction and thus may be beneficial in patients with HCM. In 2015 results of a first study were published (Klempfner et al.), which showed that the majority of HCM patients with moderate risk undergoing supervised physical training had improved physical performance and no significant adverse events were recorded. The study was limited by the small number of admitted patients (twenty), lack of control group and failure to perform cardio-pulmonary exercise test.

The main goal of the study will be to evaluate the effectiveness and safety of comprehensive cardiological rehabilitation and telerehabilitation in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction with preserved systolic function. The study is planned to include 30 patients with HCM subjected to physical training and 30 patients with HCM in the control group treated as standard according to current guidelines, not subjected to physical training.

Condition or Disease Intervention/Treatment Phase
  • Other: Cardiac rehabilitation + standard therapy
  • Other: Standard therapy
N/A

Detailed Description

The main goal of the study will be to evaluate the effectiveness and safety of comprehensive cardiological rehabilitation and telerehabilitation in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction with preserved systolic function. The study is planned to include 30 patients with HCM subjected to physical training and 30 patients with HCM in the control group treated as standard according to current guidelines, not subjected to physical training.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
"Efficacy and Safety of Cardiac Rehabilitation in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction With Preserved Systolic Function - Pilot Study".
Actual Study Start Date :
Jul 10, 2017
Anticipated Primary Completion Date :
Dec 1, 2020
Anticipated Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: HCM patients with CR

30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)

Other: Cardiac rehabilitation + standard therapy
Patients with HCM subjected to cardiological rehabilitation
Other Names:
  • Standard therapy
  • Other: HCM patients without CR (control group)

    30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)

    Other: Standard therapy
    Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling

    Outcome Measures

    Primary Outcome Measures

    1. Peak VO2 [36 months]

      Physical efficiency evaluated in the measurable parameter - peak VO2.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Patient with hypertrophic cardiomyopathy (defined in accordance with the ESC guidelines for the diagnosis and management of cardiomyopathy and hypertrophy in 2014): thickness ≥ 15 mm of one or more segments of the left ventricular wall measured using any imaging technique [echocardiography, cardiac magnetic resonance or computed tomography] which can not be explained solely by the left ventricular loading conditions) without left ventricular outflow tract obstruction at rest: gradient <30 mmHg.

    2. Stable general condition (1 month period).

    3. NYHA Class II and III.

    4. Preserved LV systolic function (LVEF ≥ 50%).

    5. Condition after ICD implantation.

    6. Written informed consent of the patient to participate in the Program.

    7. Completed eighteen years of age.

    Exclusion Criteria:
    1. Complex life-threatening ventricular arrhythmias that can not be treated.

    2. Uncontrolled hypertension.

    3. Advanced atrio-ventricular block.

    4. Myocarditis or pericarditis (up to 6 months).

    5. Symptomatic aortic stenosis.

    6. Acute systemic illness.

    7. Intracardiac thrombosis.

    8. Significant ischaemia during low intensity exercise test (2 METS, 50W).

    9. Uncontrolled diabetes.

    10. Pulmonary embolism (up to 6 months).

    11. Thrombophlebitis.

    12. New episode of AF/Afl.

    13. Decrease in systolic blood pressure during exercise.

    14. Co-morbidities that limit exercise tolerance and prevent exercise.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Cardinal Stefan Wyszyński Institute of Cardiology Warsaw Mazowieckie Poland 04-628

    Sponsors and Collaborators

    • Institute of Cardiology, Warsaw, Poland

    Investigators

    • Principal Investigator: Krzysztof Sadowski, The Cardinal Stefan Wyszyński Institute of Cardiology

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Institute of Cardiology, Warsaw, Poland
    ClinicalTrials.gov Identifier:
    NCT03178357
    Other Study ID Numbers:
    • 2.1/I/17
    First Posted:
    Jun 6, 2017
    Last Update Posted:
    Mar 26, 2019
    Last Verified:
    Mar 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 26, 2019